Basel, May 21, 2014 - Novartis announced today new data from the QUANTIFY study, which demonstrated the non-inferiority of Ultibro® Breezhaler®(indacaterol/glycopyrronium) 110/50 mcg compared to tiotropium 18 mcg plus formoterol 12 mcg in terms of health-related quality of life (HRQoL) outcomes in moderate-to-severe chronic obstructive pulmonary disease (COPD) patients at week 26[1],[2]. Positive results from QUANTIFY are part of 16 Novartis respiratory abstracts being presented at the American Thoracic Society (ATS) International Conference, May 16-21, 2014 in San Diego, CA, USA.
Novartis announces positive results at ATS for once-daily Ultibro® Breezhaler® versus combination therapy (tiotropium plus formoterol)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.